Does Kratom Show Up on Drug Tests?

What Do Standard Drug Test Panels Actually Screen For?

Understanding why kratom is not detected requires understanding how standard drug tests work. Most workplace, pre-employment, and routine screening tests use immunoassay technology — antibody-based reagents that react to specific molecular structures. Each panel tests for a predefined set of substance classes.

The Department of Transportation (DOT) 5-panel test is the most common standard used in regulated industries (transportation, aviation, federal contractors).^[1] (transportation, aviation, federal contractors). It does not include kratom. No federal drug testing mandate currently requires kratom screening. Kratom is not a controlled substance under federal law — which is a key reason it is not part of standard federal testing frameworks.

Why Does Kratom Not Appear on Standard Drug Tests?

Immunoassay drug tests work by using antibodies that recognize specific molecular structures. An opiate immunoassay, for example, uses antibodies designed to bind to morphine, codeine, and structurally similar molecules — if the antibody binds to enough of the target molecule (or a sufficiently similar one), the test registers a positive.

Mitragynine — kratom’s primary alkaloid — has a distinct chemical structure: it is an indole alkaloid with a molecular framework that is fundamentally different from the phenanthrene ring structure of classical opiates (morphine, heroin, codeine) and the phenylpiperidine structure of synthetic opioids (fentanyl, methadone). Kruegel and Grundmann (2018) characterized mitragynine’s unique molecular architecture in their comprehensive review of kratom’s medicinal chemistry — its atypical binding profile is precisely what distinguishes it pharmacologically from classical opioids.^[1]

The practical implication: opiate immunoassay antibodies do not bind to mitragynine at clinically relevant concentrations. There is no cross-reactivity, and no false positive. This is not a regulatory gap or an oversight — it reflects the actual molecular biology of how immunoassays work and how chemically distinct mitragynine is from the compound classes these assays target.

Does Kratom Cause False Positives for Other Substances?

No — this is one of the most persistent misconceptions about kratom and drug testing. The concern typically goes: “Kratom acts on opioid receptors, so won’t it show up as an opioid?” The answer is no, for the structural chemistry reason explained above.

Immunoassay drug tests do not detect receptor activity — they detect molecular structure. Kratom can bind to mu-opioid receptors (MOR) and produce opioid-like effects precisely because its alkaloids fit the receptor’s binding pocket despite being structurally different from classical opioids. That same structural difference is why opiate immunoassays don’t detect it.

The Voelker et al. (2021) FDA study on field portable detection devices for mitragynine underscores this point: specialized detection requires specific assays designed for mitragynine’s unique chemical signature — standard opiate detection methods do not cross-detect it.^[2]

What kratom does NOT cause false positives for:

• Opiates (morphine, codeine, heroin) — different molecular class
• Synthetic opioids (oxycodone, fentanyl, hydrocodone) — different molecular class
• Methadone — different molecular class (though Suboxone patients sometimes wonder if kratom might interfere; it won’t with methadone-specific tests)
• Benzodiazepines, amphetamines, THC, cocaine, PCP — completely different pharmacological classes

If you have received a positive drug test result that you believe may be kratom-related, the explanation is almost certainly a different compound, not kratom. GC-MS or LC-MS/MS confirmatory testing — the gold standard used to confirm or refute immunoassay positives — would not confirm kratom as morphine or any other standard panel substance because they are chemically distinguishable.

When Can Kratom Be Detected? Specialized Tests Explained

Kratom can be detected — but only by tests specifically designed to identify mitragynine and/or its metabolites. These are not immunoassay tests; they use analytical chemistry techniques including:

• LC-MS/MS (liquid chromatography-tandem mass spectrometry) — the most definitive method; identifies mitragynine and metabolites by molecular mass and fragmentation pattern with high sensitivity and specificity. Used in forensic and clinical laboratories.
• GC-MS (gas chromatography-mass spectrometry) — an alternative mass spectrometry approach; also highly specific for mitragynine.
• ELISA immunoassay for mitragynine — specialized antibody-based test targeting mitragynine specifically; less common than mass spectrometry methods but faster for screening purposes. Less definitive than LC-MS/MS and may produce some cross-reactivity with structurally related alkaloids.
• Field portable devices — Voelker et al. (2021) evaluated four FDA portable devices for rapid mitragynine detection in suspected kratom products.^[2] These are primarily used for product identification in regulatory or forensic contexts, not biological specimen testing.

The key point: none of these methods are part of routine workplace screening. Ordering a kratom-specific test requires deliberate intent. It is an add-on test, not a standard component of any common panel.

In What Contexts Might Kratom-Specific Testing Be Used?

For most people in standard employment situations, kratom-specific testing is essentially never encountered. However, there are contexts where it is more likely:

• Forensic and medicolegal investigations — when kratom is suspected to have played a role in an incident, death, or impaired driving situation, forensic toxicology laboratories may include mitragynine in a broad-spectrum substance screen.
• Court-ordered drug monitoring (some jurisdictions) — probation or drug court monitoring programs vary widely. Some jurisdictions have begun adding kratom to expanded panels where a person has a history of kratom use or is in a treatment program. This is jurisdiction-specific and not universal.
• Substance use treatment programs — some inpatient and intensive outpatient treatment programs for substance use disorders include kratom monitoring, particularly for patients who have used kratom as a self-management tool for opioid withdrawal. Grundmann (2017) documented kratom’s common use in self-management contexts, including opioid self-management — which is why treatment providers increasingly ask about it.^[3]
• Clinical research and pharmacokinetic studies — controlled studies examining kratom use require confirmatory testing; Trakulsrichai et al. (2015) used LC-MS/MS for mitragynine quantification in the landmark human pharmacokinetics study.^[4]
• Some pain management or opioid treatment programs — some pain clinics and opioid treatment programs (e.g., those monitoring patients on buprenorphine or methadone) have expanded their panels to include kratom in recent years. This varies by program and is not standard.
• Life insurance and medical evaluations — some high-value life insurance policies or health evaluations include expanded substance testing; kratom inclusion is uncommon but possible in 2026 given its increased profile.

For routine pre-employment, random workplace, return-to-duty, and DOT-regulated testing: kratom is not screened and will not appear. If you are uncertain about a specific test, ask the administering Medical Review Officer (MRO) or the testing lab directly what substances are included in the panel.

What Are the Detection Windows If Specifically Tested For?

If a test specifically screens for mitragynine, detection windows depend on the type of biological specimen and frequency of use. Trakulsrichai et al. (2015) established a mean mitragynine half-life of 9 hours in humans, providing the pharmacokinetic foundation for estimating clearance.^[4] For detailed pharmacokinetic data on clearance timelines, see our companion guide: How Long Does Kratom Stay in Your System? — which covers the 9-hour half-life, metabolite excretion, and accumulation with daily use in full detail.

Summary of detection windows for kratom-specific testing:

• Urine: 1–3 days (occasional users); 5–9 days (daily users)
• Blood/plasma: 24–48 hours (mitragynine, parent compound)
• Hair follicle: Potentially up to 90 days (limited clinical data; depends on lab and testing methodology)

The Tanna et al. (2022) clinical pharmacokinetic study confirmed that kratom’s clearance follows multi-day kinetics consistent with the half-life data — with daily use producing accumulation that extends detection windows significantly beyond what a single-dose timeline would predict.^[5]

Frequently Asked Questions

Will kratom make me fail a drug test at work?

Almost certainly not, if you are subject to a standard workplace drug test (5-panel, 10-panel, DOT). These tests do not screen for kratom. Unless your employer has specifically added kratom to a custom expanded panel — which would be unusual and would typically require disclosure — kratom will not cause a failed test. If you are genuinely uncertain, ask the Human Resources department or occupational health provider what specific substances the test screens for. They are required to tell you.

Does kratom show up as an opioid on a drug test?

No. This is the most common misconception about kratom and drug testing. Standard opioid immunoassays target morphine, codeine, and structurally similar molecules using antibodies designed for that molecular class. Mitragynine is an indole alkaloid with a fundamentally different structure — the same immunoassay antibodies that detect morphine do not cross-react with mitragynine. Kratom can bind to opioid receptors and produce opioid-like effects, but it does so via a different molecular structure than the compounds these tests identify.

What if I’m on probation — will kratom show up on my drug test?

This depends entirely on the jurisdiction, the testing program, and whether your probation officer has specifically ordered kratom screening. Most standard probation drug tests use the same immunoassay panels as workplace testing and do not include kratom. However, some jurisdictions, particularly those with expanded drug court programs or updated testing protocols, have added kratom to their panels. The safe approach: disclose kratom use to your probation officer or attorney proactively rather than assuming it won’t be tested. Policies vary and can change without notice.

Will kratom affect a DOT drug test?

No. DOT-regulated testing (for CDL holders, aviation workers, pipeline workers, mass transit employees, etc.) uses the federal 5-panel standard. Kratom is not a federally controlled substance, is not included in the federal testing mandate, and will not appear on a DOT drug test. The DOT has not added kratom to its testing requirements as of April 2026. If this changes, it would be announced via formal rulemaking.

Can I test myself for kratom at home?

Standard at-home drug tests (the type sold at pharmacies) test for the same panel substances as standard workplace tests — and do not include kratom. A home opiate test that is negative does not tell you anything about your kratom levels. Kratom-specific home testing kits exist but are uncommon; they use either immunoassay strips designed for mitragynine or color-based reagent tests that can identify mitragynine in products but are not validated for biological specimen testing. If you need to know your kratom clearance status, a clinical laboratory can run an LC-MS/MS urine panel specifically for mitragynine.

Does the amount of kratom I use affect whether it shows up on a test?

On a standard drug test: no amount of kratom use will produce a positive because the test simply does not screen for it. On a kratom-specific test: yes, dose and frequency significantly affect detection. A single moderate dose typically clears from urine within 1–3 days. Daily use over extended periods extends this to 5–9 days or more. Higher doses are detectable for longer at any given use frequency. See our full system clearance guide for the pharmacokinetics.

What should I do if I’m concerned about an upcoming drug test?

First: find out exactly what the test screens for. Ask the administering organization, HR department, or test administrator directly. If the test is a standard 5- or 10-panel, kratom is not an issue. If it is an expanded panel or you are unsure, stop using kratom for at least 7–10 days before the test (longer if you are a daily user) to be conservative. Do not attempt to adulterate or dilute your specimen — most supervised tests include validity checks (creatinine, specific gravity) that flag diluted specimens, and specimen tampering is typically treated as a failed test.

Is kratom legal? Could it become part of standard drug testing in the future?

Kratom’s federal legal status remains unscheduled as of April 2026 — it is not a controlled substance under the Controlled Substances Act. Several states have enacted their own kratom regulations or bans (see our Kratom Legal Status guide for current state-by-state status). As kratom’s profile has grown, some state-regulated testing programs and private employers have added it to custom panels. Whether it becomes a standard federal testing target depends on future DEA, FDA, or DOT regulatory action — none of which has been finalized as of this writing.

Related Guides

References

1. Kruegel AC, Grundmann O. (2018). The medicinal chemistry and neuropharmacology of kratom: a preliminary discussion of a promising medicinal plant and analysis of its potential for abuse. Neuropharmacology. [PubMed]
2. Voelker SE, Kern SE, Falconer TM et al. (2021). Evaluation of four field portable devices for the rapid detection of mitragynine in suspected kratom products. Journal of Pharmaceutical and Biomedical Analysis. [PubMed]
3. Grundmann O. (2017). Patterns of kratom use and health impact in the US — results from an online survey. Drug and Alcohol Dependence. [PubMed]
4. Trakulsrichai S, Sathirakul K, Auparppong S et al. (2015). Pharmacokinetics of mitragynine in man. Drug Design, Development and Therapy. [PubMed]
5. Tanna RS, Nguyen JT, Hadi DL et al. (2022). Clinical pharmacokinetic assessment of kratom (Mitragyna speciosa), a botanical product with opioid-like effects, in healthy adult participants. Clinical Pharmacology & Therapeutics. [PubMed]